This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Will Flagship Impella Drive Abiomed's (ABMD) Q2 Earnings?
by Zacks Equity Research
Abiomed (ABMD) likely to gain from flagship Impella in Q2; a competitive industry is a headwind.
Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?
by Zacks Equity Research
Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.
What's in Store for Weight Watchers' (WTW) Q3 Earnings?
by Zacks Equity Research
Weight Watchers (WTW) likely to see soft segmental revenues in Q3; EPS guidance raised.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.
Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?
by Zacks Equity Research
Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.
The Zacks Analyst Blog Highlights: Becton, Occidental, Phillips, Allstate and Deutsche
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Occidental, Phillips, Allstate and Deutsche
Top Analyst Reports for Becton, Dickinson, Occidental Petroleum & Phillips 66
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Becton, Dickinson (BDX), Occidental Petroleum (OXY) and Phillips 66 (PSX).
Stock Market News For Sep 10, 2018
by Zacks Equity Research
Markets ended sharply lower on Friday after President Donald Trump said that the United States was ready to move ahead with tariffs.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.
Becton, Dickinson Hits at a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.
Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm
by Zacks Equity Research
Medtronic (MDT) focuses on initiatives to boost its diabetes business.
Becton, Dickinson Global Foothold Strong, Recalls Rampant
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.
Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.
Becton Dickinson (BDX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.11% and 0.97%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Aug 2: ABC, BDX & More
by Zacks Equity Research
Strong R&D focus is likely to be the key driver of the Medical Product space in Q2.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.
Stock Market News For Jul 12, 2018
by Zacks Equity Research
Wall Street closed sharply lower on Wednesday ending its four-day winning streak
Stock Market News For Jul 11, 2018
by Zacks Equity Research
U.S. stock markets continues their winning streak for the fourth straight session as all three major indexes ended up in positive territory on Tuesday
BD Buys TVA Medical, To Provide Minimally Invasive Procedure
by Zacks Equity Research
The acquisition of TVA Medical will enable Becton, Dickinson (BDX) to treat patients with chronic kidney disease through minimally invasive procedures.
Will Flagship Impella Drive Abiomed's (ABMD) Q1 Earnings?
by Zacks Equity Research
Abiomed's (ABMD) first-quarter fiscal 2019 earnings are likely to be driven by an exclusive Impella product line. Intense competition raises concern.
Can International Sales Drive Baxter's (BAX) Q2 Earnings?
by Zacks Equity Research
Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) gains from strong fundamentals. Recent product recall issues raise concern.